Our data suggest that sitagliptin accelerates normalization of blood glucose level in a diabetes model by stabilizing Glp-1, which in turn results in increased insulin production which may be due to an increase in β-cell mass, VEGF expression and vascularization. This evidence concerns the gene VEGFA and diabetes mellitus.